CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+53.29%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.09B
AUM Growth
+$2.09B
(+22%)
Cap. Flow
-$302M
Cap. Flow
% of AUM
-14.46%
Top 10 Holdings %
Top 10 Hldgs %
62.94%
Holding
58
New
8
Increased
12
Reduced
13
Closed
10
Top Buys
| 1 |
EyePoint Pharmaceuticals
EYPT
|
$65.6M |
| 2 |
ALX Oncology
ALXO
|
$37.7M |
| 3 |
AUTL
Autolus Therapeutics
AUTL
|
$32.6M |
| 4 |
CRGX
CARGO Therapeutics
CRGX
|
$27.4M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$25.4M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$198M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$82.3M |
| 3 |
Structure Therapeutics
GPCR
|
$53.3M |
| 4 |
BridgeBio Pharma
BBIO
|
$53.2M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$48.4M |
Sector Composition
| 1 | Healthcare | 98.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $513M | 24.5% | 8,494,151 +352,051 | +4% | +$21.3M |
|
|
AMAM
2
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $160M | 7.64% | 11,231,000 +1,307,311 | +13% | +$18.6M |
|
|
3
EyePoint Pharmaceuticals
EYPT
$797M
| $140M | 6.66% | 6,038,235 +2,838,235 | +89% | +$65.6M |
|
|
4
BridgeBio Pharma
BBIO
$9.89B
| $135M | 6.45% | 3,344,179 -1,318,351 | -28% | -$53.2M |
|
5
Arcellx
ACLX
$3.85B
| $94.4M | 4.51% | 1,700,000 -450,000 | -21% | -$25M |
|
|
RYZB
6
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $75.4M | 3.6% | 1,213,478 +31,215 | +3% | +$1.94M |
|
7
Biomea Fusion
BMEA
$116M
| $51.8M | 2.48% | 3,570,872 | – | – |
|
8
Immunovant
IMVT
$2.56B
| $49.1M | 2.34% | 1,165,000 -60,000 | -5% | -$2.53M |
|
|
ALPN
9
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $48.6M | 2.32% | 2,550,000 +650,000 | +34% | +$12.4M |
|
10
Pharvaris
PHVS
$1.39B
| $48M | 2.29% | 1,711,460 +350,000 | +26% | +$9.82M |
|
|
11
ALX Oncology
ALXO
$62.7M
| $46.8M | 2.23% | 3,142,079 +2,530,000 | +413% | +$37.7M |
|
12
Tarsus Pharmaceuticals
TARS
$2.47B
| $45M | 2.15% | 2,221,422 -400,000 | -15% | -$8.1M |
|
|
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
| $42.5M | 2.03% | 1,800,000 -2,050,000 | -53% | -$48.4M |
|
14
Vaxcyte
PCVX
$4B
| $41.8M | 1.99% | 665,000 | – | – |
|
15
Crinetics Pharmaceuticals
CRNX
$2.92B
| $40.9M | 1.95% | 1,150,000 +48,096 | +4% | +$1.71M |
|
|
16
Apellis Pharmaceuticals
APLS
$3.48B
| $37.4M | 1.79% | 625,000 -1,375,000 | -69% | -$82.3M |
|
|
MRNS
17
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $35.3M | 1.69% | 3,250,000 +625,000 | +24% | +$6.79M |
|
|
AUTL
18
Autolus Therapeutics
AUTL
$399M
| $35.1M | 1.68% | 5,450,000 +5,057,833 | +1,290% | +$32.6M |
|
19
Olema Pharmaceuticals
OLMA
$375M
| $34.5M | 1.65% | 2,456,800 -2,047,964 | -45% | -$28.7M |
|
20
Immuneering
IMRX
$245M
| $30.9M | 1.48% | 4,204,364 | – | – |
|
21
Edgewise Therapeutics
EWTX
$1.51B
| $27.9M | 1.33% | 2,551,989 -394,898 | -13% | -$4.32M |
|
|
JBIO
22
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $27.4M | 1.31% | 1,211,696 -350,000 | -22% | -$7.92M |
|
|
CRGX
23
DELISTED
CARGO Therapeutics
CRGX
| $27.4M | 1.31% | +1,182,563 | New | +$27.4M |
|
|
24
Syndax Pharmaceuticals
SNDX
$1.41B
| $25.4M | 1.21% | +1,175,000 | New | +$25.4M |
|
25
Korro Bio
KRRO
$217M
| $25.4M | 1.21% | +529,170 | New | +$25.4M |
|